Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.
Clinical trial NCT05346666 · UNKNOWN
Trial details
- NCT number
- NCT05346666
- Sponsor
- Damanhour University
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-25
- Primary completion
- 2023-09-20
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.